In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
PK sparse sampling scheme optimization for phase III clinical trial in Oncology
The Sponsor intended to have a bio-predictive media followed by IVIVR model to predict the plasma exposure for different in-vitro release and different doses. The
Enhancing the efficacy of a COVID-19 Vaccine
In silico MD clinical trial in children 12-18 years of age
The Sponsor intended to have a “dissolution safe space” based on the bio batch dissolution specifications. The Sponsor had performed a BA BE study and
Augmenting Tuberculosis clinical trials with a Synthetic Arm
In Silico trial to optimize formulation composition of transdermal patch for achieving bioequivalence
In Silico trial to replace Bioequivalence trial for formulation with different particle size distribution (PSD)